Serum level of IGFBP3 and IGF1/IGFBP3 molar ratio in addition to PSA and single nucleotide polymorphism in PSA and CYP17 gene may contribute to early diagnostics of prostate cancer

• DOI: 10.4149/neo_2010_02_118
• Publication Date: 2010-02-03T16:26:09Z
• Authors: M. Tajtakova; A. Pidanicova; L. Valansky; L. Lachvac; V. Nagy; M. Sivonova; D. Dobrota; J. Kliment; J. Petrovicova
• Keywords: IGFBP3; Gene polymorphism; Molar ratio

The aim of the paper is to determine whether IGF1, IGFBP3 and IGF1/IGFBP3 molar ratio in addition PSA one-nucleotide polymorphism CYP17 gene might contribute early diagnostics prostate cancer (PCa). Serum level PSA, IGF1 group 158 individuals (92 PCa 66 controls) was examined by RIA method calculated. PCR RLFP used examine one- nucleotide CYP 17 gene. results suggest that serum over 95% CI did not increase relative risk development overall group, even regarding particular investigated genotypes, if with genotype AG+A1A1, AG+A1A2, GG+A1A1 GG+A1A2 were evaluated. under increased group(chi(2) = 10,03, p= 0,001, OR 3,12, 1,44-6,93), as well AG(chi(2) 4,72 0,029, 2,87, 01,09-7,49) A1A1(chi(2) 3,76 0,052, 2,57, 0,97-6,75). association between frequencies occurrence higher confirmed, nor for CYP17, however (chi(2) 1,58, 0,208, 1,67, 0,75-3,71) more than 1, combination AG+A1A1,AG+ A1A2. PCa. Further research needed prove, determines prognosis progression